KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $106.2 million.

  • Amneal Pharmaceuticals' Free Cash Flow fell 1496.21% to $106.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $264.3 million, marking a year-over-year decrease of 71.37%. This contributed to the annual value of $243.2 million for FY2024, which is 1957.46% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Free Cash Flow stood at $106.2 million for Q3 2025, which was down 1496.21% from $61.0 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Free Cash Flow high stood at $136.4 million for Q1 2021, and its period low was -$130.6 million during Q2 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' median Free Cash Flow value was $69.7 million (recorded in 2023), while the average stood at $48.4 million.
  • In the last 5 years, Amneal Pharmaceuticals' Free Cash Flow tumbled by 17595.22% in 2022 and then surged by 46238.56% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Free Cash Flow (Quarter) stood at $45.8 million in 2021, then tumbled by 175.95% to -$34.8 million in 2022, then skyrocketed by 462.39% to $126.0 million in 2023, then dropped by 18.29% to $102.9 million in 2024, then grew by 3.14% to $106.2 million in 2025.
  • Its last three reported values are $106.2 million in Q3 2025, $61.0 million for Q2 2025, and -$5.8 million during Q1 2025.